{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:08:07Z","timestamp":1788404887366,"version":"build-2803163510"},"reference-count":44,"publisher":"Informa UK Limited","issue":"12","funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/14740338.2024.2343015","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T14:50:20Z","timestamp":1713279020000},"page":"1391-1403","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3584-6212","authenticated-orcid":false,"given":"Beema T","family":"Yoosuf","sequence":"first","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-6839","authenticated-orcid":false,"given":"Muhammed","family":"Favas KT","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Dutta","sequence":"additional","affiliation":[{"name":"Postgraduate Institute of Medical Education and Research","place":["Chandigarh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4520-3293","authenticated-orcid":false,"given":"Dipika","family":"Bansal","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0399-8"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.05.025"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2015.05.465"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.14.39"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.141319"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-0407.2011.00143.x"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2016.09.003"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.34.1.3"},{"key":"e_1_3_6_10_1","unstructured":"NICE guideline on type 2 diabetes in adults: management 2022. [cited 2023 Feb 7] Available from: https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/visual-summary-full-version-choosing-medicines-for-firstline-and-further-treatment-pdf-10956472093"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-27301-9"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.11.010"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"e_1_3_6_15_1","unstructured":"FDA drug safety communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. [cited 2023 Jun 10] Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes"},{"key":"e_1_3_6_16_1","unstructured":"FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. [cited 2023 Jun 10]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain#:~:text=FDA%20Drug%20Safety%20Communication%3A%20FDA cause%20severe%20joint%20pain%20%7C%20FDA"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619865413"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-00447-w"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17366-x"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0408-2"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1668373"},{"key":"e_1_3_6_22_1","unstructured":"FDA adverse event reporting system (FAERS) Public Dashboard Available from: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis"},{"key":"e_1_3_6_23_1","unstructured":"OpenVigil 2.1-MedDRA-v24 (2004Q1-2023Q1). [cited Jun 2023]. Available from: https:\/\/openvigil.sourceforge.net\/"},{"key":"e_1_3_6_24_1","unstructured":"Medical Dictionary for regulatory activities MedDRA Version 26.0. [cited Jun 2023]. Available from: https:\/\/tools.meddra.org\/wbb\/"},{"key":"e_1_3_6_25_1","unstructured":"Practical aspects of signal detection in pharmacovigilance; Report of CIOMS working group VIII. [cited 2022 Nov] Available from: https:\/\/cioms.ch\/wp-content\/uploads\/2018\/03\/WG8-Signal-Detection.pdf"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6812"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X162746"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1135"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0764"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2018.07.004"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS15-3009"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0648-x"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107503"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2710-7"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.7592"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.05.013"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32131-2"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-19055-6"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12176"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-21-0042"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00625-4"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-32824-6_5"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.10.2988"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-013-0544-0"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2024.2343015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:04:26Z","timestamp":1764921866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2024.2343015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/14740338.2024.2343015"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2024.2343015","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}